Novartis, helped by cost cuts, raises full-year outlook
By Ludwig Burger FRANKFURT (Reuters) -Novartis on Tuesday raised its full-year earnings outlook following cost cuts, a breast cancer drug trial success and progress in boosting output of a radiotherapy drug against prostate cancer. The Swiss drugmaker said in a statement that excluding Sandoz, a generic drug division to be spun off in the second …
Novartis, helped by cost cuts, raises full-year outlook Read More »









